News: Articles and Publications

Gates MRI and IQVIA Partner to Advance R&D in Low- And Middle-Income Countries

June 25, 2026•Press Release

The Gates Medical Research Institute (Gates MRI) has entered into an expanded, strategic collaboration with IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, to streamline trial operations and accelerate its clinical portfolio.

Charles Wells, MD, Appointed Chief Medical Officer and Head of Medical Development at Gates MRI

May 20, 2026•Press Release

The Gates Medical Research Institute (MRI) today announced the appointment of Charles Wells, MD, as Chief Medical Officer (CMO) and Head of Medical Development, effective May 15, 2026.

Design and feasibility considerations for a Phase 3 efficacy trial of the M72/AS01E-4 tuberculosis vaccine

May 12, 2026•Vaccine

Building and managing a complex drug discovery consortium: insights from the tuberculosis drug accelerator

April 30, 2026•Drug Discovery Today

Impact of Bifidobacterium infantis supplementation on growth, health outcomes, and gut microbiome features in underweight infants from Pakistan

April 28, 2026•Frontiers in Nutrition

Interferon-gamma release assay positivity in populations at high risk of TB infection

April 14, 2026•IJTLD CRD

A mixed-method study to inform the development of long-acting injectable TB treatments

April 14, 2026•IJTLD CRD

Krishnan Ramanathan, PhD, Appointed as Interim Chief Executive Officer of Gates Medical Research Institute

April 1, 2026•Press Release

Krishnan (Krish) Ramanathan, who has served as Chief of Staff and Head of Development at Gates Medical Research Institute (MRI), has been named Interim Chief Executive Officer (CEO) of the organization.

Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis

January 13, 2026•Nature Medicine

Bifidobacterium longum subsp. infantis and Lacticaseibacillus rhamnosus GG protect intestinal epithelium against inflammation-mediated damage in an immunocompetent in-vitro model

October 13, 2025•MDPI

CMC For Long-Acting Injectables For TB

October 3, 2025•Drug Delivery Leader

Safety And Pharmacokinetics In LMIC Clinical Trials

October 2, 2025•Clinical Leader

Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial

September 23, 2025•The Lancet

The Phase 3 Clinical Trial of the M72/ASO1E tuberculosis (TB) Vaccine Candidate Has Reached Full Enrollment

April 16, 2025•Press Release

We’re glad to announce that the Phase 3 clinical trial of the M72/AS01E tuberculosis (TB) vaccine candidate has reached full enrollment eleven months ahead of schedule– with approximately 20,000 participants enrolled.

Group-based trajectory modeling to describe the geographical distribution of tuberculosis notifications

February 27, 2025•Springer